Use of prophylactic lamivudine and mycophenolate mofetil in renal transplant recipients with chronic hepatitis B infection

Pediatric Transplantation

Volumn 7, Issue 5, 2003, Pages 376-380

  Lau, S C ^a   Tse, K C ^a   Lai, W M ^a   Chiu, Man Chun ^a  

^a PRINCESS MARGARET HOSPITAL   (Hong Kong)

Author keywords

Chronic hepatitis B infection; Lamivudine; Mycophenolate mofetil; Renal transplant

Indexed keywords

ALANINE AMINOTRANSFERASE; AZATHIOPRINE; CYCLOSPORIN A; HEPATITIS B ANTIGEN; IMMUNOSUPPRESSIVE AGENT; LAMIVUDINE; LIVER ENZYME; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; VIRUS DNA;

ADOLESCENT; ADULT; ARTICLE; CASE REPORT; DIARRHEA; DISEASE EXACERBATION; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEPATITIS B; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVER FUNCTION; LIVER TOXICITY; MALE; MORBIDITY; MORTALITY; POSTOPERATIVE PERIOD; SAFETY; SIDE EFFECT; VIRUS INHIBITION; VIRUS LOAD;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBIOTIC PROPHYLAXIS; ANTIVIRAL AGENTS; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B, CHRONIC; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LAMIVUDINE; MALE; MYCOPHENOLIC ACID; TREATMENT OUTCOME;

EID: 0142022913     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3046.2003.00041.x     Document Type: Article

References (28)

1. DEGOS F. Hepatitis B virus and hepatitis B-related infection in renal transplant recipients. Gastroentrology 1988: 94: 151-156.
2. DHAR JM. The significance and implications of hepatitis B infection in renal transplant recipients. Transplant proc 1991: 23:1785-1786.
3. FAIRLEY CK, MIJCH A, GUST ID, et al. The increased risk of fatal liver disease in renal transplant patients who are hepatitis Be antigen and/or HBV DNA positive. Transplantation 1991: 52: 497-500.
4. LAM PW, et al. Fibrosing cholestatic hepatitis in renal transplant recipicnts. Transplantation 1996:61:378-381.
5. WAGURI N, ICHIDA T, FUJIMAKI R, et al. Fibrosing cholestatic hepatitis after living related-donor renal transplantation. J Gastrocnterol Hepatol 1998: 13: 1133-1137.
6. MAYNARD JE. Hepatitis B global importance and need for control. Vaccine 1990: 8(Suppl): S18-S20.
7. WONG KM. Long-term outcome in hepatitis B sero-positive oriental renal transplant recipients. Transplant Proc 2001: 33: 1242-1244
8. ROSTAING LIONEL. Efficacy and safety of lamivudine on replication of recurrent hepatitis B after cadaveric renal transplantation. Transplantation 1997: 64: 1624-1627.
9. LAI CL. One-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998: 339: 61-68.
10. YOUNG OK JUNG. Treatment of chronic hepatitis B with lamivudine in renal transplant recipients. Transplantation 1998: 66: 733-737.
11. AL FARAIDY, YOSHIDA EM, DAVlS JE, et al. Alteration of the dismal natural history of fibrosing cholestatic hepatitis secondary to hepatitis B virus with the use of lamivudine. Transplantation 1997: 64: 926-928.
12. HAN DUCK J. Results on preemptive or prophylactic treatment of lamivudine in HbsAg (+) renal allograft recipients: comparison with salvage treatment after hepatic dysfunction with HBV recurrence. Transplantation 2001: 71: 387-394.
13. YING C. Ribavirin and mycopheolic acid potentiate the activity of guanine and diaminopurine-based nucleoside analogues against hepatitis B virus. Antiviral Res 2000: 48: 117-124.
14. FORNARION, S. The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection. Transplantation 1996: 62: 297-299.
15. ROSTAING L, MODESTO A, BARON E, et al. Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Nephron 1996: 74: 512-516.
16. LOK ANNA SF. Alpha-interferon therapy for chronic hepatitis B virus infection in children and oriental patients. J Gastroenterol Hepatol 1991: I(Suppl.): 15-17.
17. GOFFIN ERRIC. Lamnivudine inhibits hepatitis B virus replication in kidney graft recipients. Transplantation 1998:66:407-409.
18. GONG ZJ. Mycopheonlic acid, an immunosuppressive agent, inhibits HBV replication in vitro. J Hepat 1999: 6: 229-236.
19. CHAN HENRY LY. Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong. Hepatology 2000: 31: 763-768.
20. KAZUAKI CHAYAMA. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998: 27: 1711-1716.
21. KLETZMAYR JOSEF. Twelve months of lamivudine treatment for chronic hepatitis B virus infection in renal transplant recipients. Transplantation 2000: 70: 1404-1407.
22. FONTAINE HÉLÈNE. HBV genotypic resistance to Lamivudine in kidney recipients and hemodialyzed patients. Transplantation 2000: 69: 2090-2094.
23. JONAS MAUREEN M. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002: 346: 1706-1713.
24. NANCY LEUNG. Hepatitis B surface antigen-positive organ transplantation recipients: can lamivudine alter their fate? J Gastroenterol Hepatol 2001: 16: 955-957.
25. RAO K. Chronic viral hepatitis enhances the risk of infection but not acute rejection in renal transplant recipients. Transplantation 1996: 62: 1765-1769.
26. DE MAN RA. A randomized placebo-controlled study to evaluate the efficacy of the 12-months famiciclovir treatment in patients with chronic Hbe-Ag-positive hepatitis B. Hepatology 2000: 32: 413-417.
27. PETERS MARION G. Fulminant Hepatic Failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and Hepatitis B lmmunglobulin. Transplantation 1999: 68: 1912-1914.
28. SEEHOFER DANIEL. Additional interferon alpha for lamivudinc resistant hepatitis B infection after liver transplantation: a preliminary report. Transplantation 2000: 69: 1739-1742.